Literature DB >> 16159720

Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide.

Lu-Chun Wang1, Chung-May Yang.   

Abstract

PURPOSE: To investigate clinical findings and ocular characteristics of sterile endophthalmitis following intravitreal injection (IVI) of triamcinolone for the treatment of macular edema.
METHODS: IVI is an institutional practice at our hospital. From March 2002 to January 2003, a total of 21 IVIs of triamcinolone acetonide were performed on 19 patients with macular edema secondary to various retinal disorders. Cases diagnosed as sterile endophthalmitis after IVI of triamcinolone were selected for the study. Fisher's discriminant linear analysis was used to determine whether a significant correlation existed between specific ocular features and the occurrence of post-injection sterile endophthalmitis.
RESULTS: Five of 21 eyes (23.8%) had sterile endophthalmitis with hypopyon formation after the injection. Of the five sterile endophthalmitis patients, three were pseudophakic with impaired posterior capsule and four had a diagnosis of Irvine-Gass syndrome. The rate of sterile endophthalmitis was significantly higher in pseudophakic patients with impaired posterior capsule (p = 0.0075) and in patients with Irvine-Gass syndrome (p = 0.0008). The best-corrected visual acuity (BCVA) in these patients remained unchanged or even improved when the inflammation subsided.
CONCLUSION: Pseudophakia with impaired posterior capsule and the diagnosis of cystoid macular edema due to Irvine-Gass syndrome are two risk factors of sterile endophthalmitis following IVI triamcinolone. No loss of BCVA was noted in the patients with post-injection sterile endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16159720     DOI: 10.1080/09273940590951007

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  9 in total

1.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

Review 2.  [Treatment of postoperative endophthalmitis : Operate or only inject?]

Authors:  L Mautone; C Skevas; M S Spitzer
Journal:  Ophthalmologe       Date:  2021-02-10       Impact factor: 1.059

3.  Associated factors and treatment outcome of presumed noninfectious endophthalmitis occurring after intravitreal triamcinolone acetonide injection.

Authors:  Seong Joon Ahn; Tae Wan Kim; Jeeyun Ahn; Jang Won Huh; Hyeong Gon Yu; Hum Chung
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-22       Impact factor: 3.117

4.  Confirmed Candida albicans endogenous fungal endophthalmitis in a patient with chronic candidiasis.

Authors:  A Hassan; W Poon; M Baker; C Linton; F A Mühlschlegel
Journal:  Med Mycol Case Rep       Date:  2012-06-16

Review 5.  Sterile endophthalmitis after intravitreal injections.

Authors:  Joaquín Marticorena; Vito Romano; Francisco Gómez-Ulla
Journal:  Mediators Inflamm       Date:  2012-08-29       Impact factor: 4.711

6.  Sterile endophthalmitis rates and particle size analyses of different formulations of triamcinolone acetonide.

Authors:  David G Dodwell; Darrel A Krimmel; Christopher M de Fiebre
Journal:  Clin Ophthalmol       Date:  2015-06-09

7.  Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: a survey study.

Authors:  Matthew McHarg; LeAnne Young; Natasha Kesav; Mehmet Yakin; H Nida Sen; Shilpa Kodati
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-01-04

8.  Drug-induced uveitis.

Authors:  Nikolas Js London; Sunir J Garg; Ramana S Moorthy; Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-03-25

Review 9.  Intravitreal therapeutic agents in noninfectious uveitic macular edema.

Authors:  Kunal Kaushik Shah; Parthopratim Dutta Majumder; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2018-08       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.